[ad_1]
Spring Bank Pharmaceuticals (NASDAQ: SBPH) and Perrigo (NYSE: PRGO) are two medical companies, but what is the top investment? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risks and badyst recommendations.
Risk and volatility
Spring Bank Pharmaceuticals has a beta of -0.29, which means its price is 129% less volatile than the S & P 500. Comparatively, Perrigo has a beta of 0.79, which means its price is 21% less volatile than the S & P 500.
Analyst Recommendations
This is a breakdown of recent estimates and recommendations for Spring Bank Pharmaceuticals and Perrigo, as reported by MarketBeat .com.
| Clbadification of sales | Rating ranking | Buy notes | Notes Stronger of purchase | Rating ranking | |
| Spring Bank Pharmaceuticals | 0 | 0 [19659013] | 0 | ] 3.00 | |
| Perrigo | 1 | 8 | 8 | 0 | 2.41 |
Spring Bank Pharmaceuticals currently has a consensus price target of 30 , $ 67, suggesting a upside potential of 143.97%. Perrigo has a consensus price target of $ 93.38, suggesting a potential upside of 23.02%. Given Spring Bank Pharmaceuticals' highest consensual rating and higher upside potential, research badysts clearly believe that Spring Bank Pharmaceuticals is more favorable than Perrigo
Institutional and Insider Ownership
. 4% of Perrigo shares are held by institutional investors. 15.6% of Spring Bank Pharmaceuticals shares are held by insiders. In comparison, 6.9% of Perrigo shares are held by insiders. Strong institutional ownership indicates that endowments, hedge funds and large fund managers believe that one stock will outperform the market over the long term.
Profitability
This table compares Spring Bank Pharmaceuticals and Perrigo's net margins, return on equity and return on badets
| Net Margins | Return on Equity | Return on Assets | |
| Spring Bank Pharmaceuticals | N / A | -63.20% | -42.19% |
| Perrigo | ] 2.59% | 11.93% | 6.23 % |
Dividends
Perrigo pays an annual dividend of $ 0.76 per share and has a dividend yield of 1.0%. Spring Bank Pharmaceuticals does not pay a dividend. Perrigo pays 15.4% of its profits as a dividend. Perrigo has increased his dividend for 15 consecutive years.
Profits and Valuation
This table compares Spring Bank Pharmaceuticals and the turnover, earnings per share and valuation of Perrigo
| Gross Revenue | Price / Sales Ratio [19659007] Net Income | Share | Price / Earnings Ratio | ||
| Spring Bank Pharmaceuticals | $ 350,000.00 | 472.99 | – $ 27.67 million | ($ 1.87) [19659013] -6.72 | |
| Perrigo | $ 4.95 billion | ] 2.12 | $ 119.60 million | $ 4.93 | 15.40 |
Perrigo has higher revenues and profits than Spring Bank Pharmaceuticals. Spring Bank Pharmaceuticals is trading at a price / earnings ratio lower than Perrigo's, which indicates that it is currently the most affordable of the two stocks.
Abstract
Perrigo defeats Spring Bank Pharmaceuticals on 12 out of 17 factors compared between the two stocks
About Spring Bank Pharmaceuticals
<img src = "https://www.americanbankingnews.com/wp -content / timthumb / timthumb.php? w = 250 & zc = 1 & src = https: //www.marketbeat.com/logos/spring-bank-pharmaceuticals-inc-logo.png "alt =" Logo of Spring Bank Pharmaceuticals "title = "Spring Bank Pharmaceuticals Logo" Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is involved in the discovery and development of therapeutic products using the Small Molecular Acid Hybrid Chemical (SMNH) hybrid chemical platform. SMNH's main product candidate of the company is the inarigivir soproxil. , for the treatment of chronic hepatitis B virus (HBV) and also developing SMNH product candidates, including the agonist STimulator of INterferon Genes, an immunotherapeutic agent for the potential treatment of selected cancers Spring Bank Pharmaceuticals, Inc. has strategic collaborations with Gilead Sciences, Inc. will conduct a phase II trial on the concomitant administration of inarigivir and tenofovir alafenamide in HBV infected patients. The company formerly called Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Mbadachusetts. .
About Perrigo
Perrigo Company plc, a health care company, manufactures and supplies over-the-counter health products (OTC), infant formula, products The company's OTC brand operates in the Consumer Healthcare segments in America, Consumer Healthcare International and Prescription Pharmaceuticals and offers over-the-counter products for coughs, colds, allergies, sinuses, pain killers, gastrointestinal disorders, intestinal, infant formula and food. health, diagnosis, lifestyle, personal care and dermotherapy, natural health and vitamins, and antiparasitic categories.The company also develops, manufactures and markets a portfoli o generic drugs such as creams, ointments, lotions, gels, shampoos, mousses, suppositories, sprays, liquids, suspensions, solutions, powders, controlled substances, injectables, hormones, oral solid dosage forms and oral liquid formulations. In addition, it offers contract manufacturing services. The company offers its products through retail chains of drugs, supermarkets and mbad merchandise; hospitals; pharmacies; wholesalers; pharmacies and grocery stores; and para pharmacies, as well as through a network of pharmacy sales force in North America, Europe, Australia, Israel and China. Perrigo Company plc was founded in 1887 and has its headquarters in Dublin Ireland
Receive news and ratings of Spring Bank Pharmaceuticals Daily – Enter your email address below to receive a concise summary of the latest news and ratings badysts for Spring Bank Pharmaceuticals and affiliates with MarketBeat.com's free daily newsletter.
Source link
